UNLABELLED: Infantile cholestatic disorders arise in the context of progressively developing intrahepatic bile ducts. Biliary atresia (BA), a progressive fibroinflammatory disorder of extra- and intrahepatic bile ducts, is the most common identifiable cause of infantile cholestasis and the leading indication for liver transplantation in children. The etiology of BA is unclear, and although there is some evidence for viral, toxic, and complex genetic causes, the exclusive occurrence of BA during a period of biliary growth and remodeling suggests an importance of developmental factors. Interestingly, interferon-γ (IFN-γ) signaling is activated in patients and in the frequently utilized rhesus rotavirus mouse model of BA, and is thought to play a key mechanistic role. Here we demonstrate intrahepatic biliary defects and up-regulated hepatic expression of IFN-γ pathway genes caused by genetic or pharmacological inhibition of DNA methylation in zebrafish larvae. Biliary defects elicited by inhibition of DNA methylation were reversed by treatment with glucocorticoid, suggesting that the activation of inflammatory pathways was critical. DNA methylation was significantly reduced in bile duct cells from BA patients compared to patients with other infantile cholestatic disorders, thereby establishing a possible etiologic link between decreased DNA methylation, activation of IFN-γ signaling, and biliary defects in patients. CONCLUSION: Inhibition of DNA methylation leads to biliary defects and activation of IFN-γ-responsive genes, thus sharing features with BA, which we determine to be associated with DNA hypomethylation. We propose epigenetic activation of IFN-γ signaling as a common etiologic mechanism of intrahepatic bile duct defects in BA.
UNLABELLED: Infantile cholestatic disorders arise in the context of progressively developing intrahepatic bile ducts. Biliary atresia (BA), a progressive fibroinflammatory disorder of extra- and intrahepatic bile ducts, is the most common identifiable cause of infantile cholestasis and the leading indication for liver transplantation in children. The etiology of BA is unclear, and although there is some evidence for viral, toxic, and complex genetic causes, the exclusive occurrence of BA during a period of biliary growth and remodeling suggests an importance of developmental factors. Interestingly, interferon-γ (IFN-γ) signaling is activated in patients and in the frequently utilized rhesus rotavirusmouse model of BA, and is thought to play a key mechanistic role. Here we demonstrate intrahepatic biliary defects and up-regulated hepatic expression of IFN-γ pathway genes caused by genetic or pharmacological inhibition of DNA methylation in zebrafish larvae. Biliary defects elicited by inhibition of DNA methylation were reversed by treatment with glucocorticoid, suggesting that the activation of inflammatory pathways was critical. DNA methylation was significantly reduced in bile duct cells from BA patients compared to patients with other infantile cholestatic disorders, thereby establishing a possible etiologic link between decreased DNA methylation, activation of IFN-γ signaling, and biliary defects in patients. CONCLUSION: Inhibition of DNA methylation leads to biliary defects and activation of IFN-γ-responsive genes, thus sharing features with BA, which we determine to be associated with DNA hypomethylation. We propose epigenetic activation of IFN-γ signaling as a common etiologic mechanism of intrahepatic bile duct defects in BA.
Authors: Mark Davenport; Sarah A Tizzard; James Underhill; Giorgina Mieli-Vergani; Bernard Portmann; Nedim Hadzić Journal: J Pediatr Date: 2006-09 Impact factor: 4.406
Authors: Randolph P Matthews; Nicolas Plumb-Rudewiez; Kristin Lorent; Paul Gissen; Colin A Johnson; Frederic Lemaigre; Michael Pack Journal: Development Date: 2005-12 Impact factor: 6.868
Authors: Limin Chen; Andrew Goryachev; Jin Sun; Peter Kim; Hui Zhang; M James Phillips; Pascale Macgregor; Sylvie Lebel; Aled M Edwards; Qiongfang Cao; Katryn N Furuya Journal: Hepatology Date: 2003-09 Impact factor: 17.425
Authors: Dong-Yi Zhang; Gregg Sabla; Pranavkumar Shivakumar; Greg Tiao; Ronald J Sokol; Cara Mack; Benjamin L Shneider; Bruce Aronow; Jorge A Bezerra Journal: Hepatology Date: 2004-04 Impact factor: 17.425
Authors: Kunal Rai; Lincoln D Nadauld; Stephanie Chidester; Elizabeth J Manos; Smitha R James; Adam R Karpf; Bradley R Cairns; David A Jones Journal: Mol Cell Biol Date: 2006-10 Impact factor: 4.272
Authors: Manali Dimri; Cassandra Bilogan; Lain X Pierce; Gregory Naegele; Amit Vasanji; Isabel Gibson; Allyson McClendon; Kevin Tae; Takuya F Sakaguchi Journal: Development Date: 2017-07-15 Impact factor: 6.868
Authors: Kathleen B Schwarz; Barbara H Haber; Philip Rosenthal; Cara L Mack; Jeffrey Moore; Kevin Bove; Jorge A Bezerra; Saul J Karpen; Nanda Kerkar; Benjamin L Shneider; Yumirle P Turmelle; Peter F Whitington; Jean P Molleston; Karen F Murray; Vicky L Ng; René Romero; Kasper S Wang; Ronald J Sokol; John C Magee Journal: Hepatology Date: 2013-09-19 Impact factor: 17.425
Authors: Shuang Cui; Melissa Leyva-Vega; Ellen A Tsai; Steven F EauClaire; Joseph T Glessner; Hakon Hakonarson; Marcella Devoto; Barbara A Haber; Nancy B Spinner; Randolph P Matthews Journal: Gastroenterology Date: 2013-01-18 Impact factor: 22.682
Authors: Danhua Zhang; Vladislav S Golubkov; Wenlong Han; Ricardo G Correa; Ying Zhou; Sunyoung Lee; Alex Y Strongin; P Duc Si Dong Journal: Dev Biol Date: 2014-08-29 Impact factor: 3.582